A pharmaceutical combination and uses thereof

By using drug compositions A, B, C, and D in combination, the problem of existing drugs being unable to completely eliminate tuberculosis bacteria has been solved, achieving the effect of reducing lung inflammation and fibrosis and reducing the recurrence of tuberculosis.

CN117045657BActive Publication Date: 2026-05-26GUANGZHOU JOYO PHARMATECH CO LTD +1
2 Cites 0 Cited by

Patent Information

Application Number
CN202310533570.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2022-05-12
Filing Date
2023-05-11
Publication Date
2026-05-26
Estimated Expiration
2043-05-11

AI Technical Summary

Technical Problem

Existing drugs for treating tuberculosis are insufficient to completely eradicate the bacteria and control tuberculosis recurrence. In particular, when fibrotic lesions are present in the lungs, the drugs are unable to completely eliminate the tuberculosis bacteria, increasing the risk of recurrence.

Method used

A drug combination is provided, comprising substance A (compound I or a pharmaceutically acceptable salt thereof), substance B (isoniazid or a pharmaceutically acceptable salt thereof), substance C (rifampin or a pharmaceutically acceptable salt thereof), and substance D (pyrazinamide or a pharmaceutically acceptable salt thereof), which, by adjusting the proportions of the components and the administration method, reduces alveolar inflammation, inflammatory lung injury caused by pulmonary tuberculosis, and secondary fibrosis caused by pulmonary tuberculosis, and increases the penetration of anti-tuberculosis drugs into the lesion site.

Benefits of technology

This drug combination can significantly reduce alveolar inflammation and secondary fibrosis caused by pulmonary tuberculosis, improve the penetration of anti-tuberculosis drugs at the lesion site, and reduce the risk of tuberculosis recurrence, especially the recurrence rate in spleen and lung tissues.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The application discloses a kind of drug combination and its application.The application provides a kind of drug combination or pharmaceutical composition, the active component of the drug combination or pharmaceutical composition includes material A, material B, material C and material D;Material A is compound I or its pharmaceutically acceptable salt;Material B is isoniazid (H) or its pharmaceutically acceptable salt;Material C is rifampicin (R) or its pharmaceutically acceptable salt;Material D is pyrazinamide (Z) or its pharmaceutically acceptable salt.The drug combination or pharmaceutical composition of the application can reduce alveolar inflammation, pulmonary tuberculosis inflammatory lung injury and pulmonary tuberculosis secondary fibrosis, while increasing the penetration of anti-tuberculosis drugs in the lesion site, to accelerate the treatment response, reduce the risk of recurrence.
Need to check novelty before this filing date? Find Prior Art